Thermo Fisher Scientific Human SARM Synthetic Peptide

Applications

Control (Ctrl)

• Assay-dependent

Blocking Assay (BLOCK)

• Assay-dependent

Product Specifications

Product Specific Information

This peptide corresponds to a 16 amino acid sequence near the amino terminus of human SARM.
PEP-1444 can be used as a blocking peptide with polyclonal antibody PA5-34402.

Target Information

SARM1 is a NAD(+) hydrolase playing a key role in axonal degeneration following injury by regulating NAD(+) metabolism (PubMed:25908823, PubMed:27671644, PubMed:28334607).
It acts as a negative regulator of MYD88- and TRIF-dependent toll-like receptor signaling pathways by promoting Wallerian degeneration, an injury-induced programmed subcellular death involving axonal degradation distal to the injury site (PubMed:15123841, PubMed:16964262, PubMed:20306472, PubMed:25908823).
Wallerian degeneration is triggered by NAD(+) depletion: upon injury, SARM1 is activated and catalyzes cleavage of NAD(+) into ADP-D-ribose (ADPR), cyclic ADPR (cADPR), and nicotinamide, leading to cytoskeletal degradation and axon destruction (PubMed:25908823, PubMed:28334607, PubMed:30333228, PubMed:31128467, PubMed:31439793, PubMed:31439792).
SARM1 can also hydrolyze NADP(+), but not other NAD(+)-related molecules (PubMed:29395922). It can activate neuronal cell death in response to stress (PubMed:20306472) and regulates dendritic arborization via the MAPK4-JNK pathway.
Additionally, it is involved in the innate immune response by inhibiting TICAM1/TRIF- and MYD88-dependent activation of JUN/AP-1, TRIF-dependent activation of NF-kappa-B and IRF3, and phosphorylation of MAPK14/p38 (PubMed:16964262).
[UniProt]

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.